Translational Development Acquisition (TDACW) Cash from Operations (2024 - 2026)

Translational Development Acquisition (TDACW) has reported Cash from Operations for 3 consecutive years, with -$338753.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations fell 97.7% year-over-year to -$338753.0; the trailing twelve-month figure through Jun 2026 stood at -$849378.0 (changed N/A YoY), and the FY2025 full-year result was -$608387.0, up 28.55% from the prior year.
• Cash from Operations eased to -$338753.0 in Q2 2026 per TDACW's latest filing, from -$305157.0 in the prior quarter.
• Across five years, Cash from Operations topped out at -$88105.0 in Q3 2025 and bottomed at -$810963.0 in Q4 2024.
• Historically, Cash from Operations has averaged -$294751.4 across 3 years, with a median of -$231574.0 in 2025.
• The sharpest annual moves came in 2025 and 2026: Cash from Operations surged 85.53% in 2025, then slumped 97.7% in 2026.
• Over 3 years, Cash from Operations stood at -$810963.0 in 2024, then soared by 85.53% to -$117363.0 in 2025, then tumbled by 188.64% to -$338753.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered -$338753.0, -$305157.0, and -$117363.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.